Hepatic Disease

More education that is clear and from reliable sources is needed for patients with a NASH diagnosis and their caregivers throughout the duration of the disease.

One in 5 patients identified as at risk for advanced chronic liver disease had advanced fibrosis and PCP was prompted to refer to hepatology.

TLM 2023: Primary care clinicians exposed to a FIB4-based risk stratification algorithm reported applying it routinely for patients with elevated LFTs after the introduction.

TLM 2023: Over 15 years, decompensated cirrhosis and OHE notably rose among Medicare beneficiaries with cirrhosis, exceeding 40% and 20% in 2020.

TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.

The predictive algorithm uses FibroScan-captured CAP and LSM data plus 5 clinical variables to identify advanced fibrosis in persons with MASLD.

TLM 2023: The burden of CAD is similar between persons with hepatic steatosis at low and high ASCVD risk, but rate of MACE is higher in the low-risk population.

TLM 2023: Use of rifaximin significantly reduced mean number of OHE episodes as well as hospital contacts, including ED visits and admissions.

TLM 2023: Investigators found that the protective effects of statin therapy against late stage liver disease increased with age older than 51 years.

TLM 2023: Relying solely on a primary diagnosis for overt hepatic encephalopathy underestimates the actual rate, length of stay, and costs of OHE hospitalizations.

TLM 2023: In participants with metabolic dysfunction-associated steatotic liver disease, retatrutide 8 mg and 12 mg resolved steatosis in >85% of subjects.

Driven largely by the widespread increase in diabetes and obesity, the rise in hepatic disease disparately affects minority populations and is outpacing available medical care.

NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.

The shift in naming for diseases historically known as nonalcoholic fatty liver disease will be top of mind at The Liver Meeting 2023. Get a quick look at why.

We took The Liver Meeting's 11 journey maps to educational sessions and focused on 4 that will be of interest to primary care.

Your daily dose of the clinical news you may have missed.

Among postmenopausal women taking hormones orally, the NAFLD prevalence increased from 25.3 to 29.4% while it decreased from 24 to 17.3% in those using the transdermal route.

The US Food and Drug Administration granted BTD to pegozafermin for the treatment of patients with NASH.

Resmetirom, a once-daily oral, thyroid hormone receptor (THR)-β selective agonist, targets key underlying NASH pathophysiology in the liver.

The expanded labeling for the antiviral against COVID-19 indicates no dose adjustment is required for persons across all stages of liver disease.

A daily dose of clinical news on Patient Care you may have missed.

Postmenopausal women who consumed 1 or more sugary drinks daily had a nearly 2-fold increased risk of liver cancer in a study of more than 98 000.

Factors positively associated with a timely first OAC Rx among the 41.3% who received one included male sex, certain comorbidities, other current medications, and obesity.

Your daily dose of clinical news you may have missed.

In patients with NAFLD, type 2 diabetes was found to be an independent predictor of both hepatic decompensation and incident HCC, according to meta-analysis authors. .

Your daily dose of clinical news you may have missed.

The ADA's annual update includes refined criteria for type 1 diabetes screening and detailed guidance on detection and management of NAFLD and NASH.

Pegozafermin, an investigational long-acting (FGF21) analogue, was associated with fibrosis improvement and NASH resolution in an average of 25% of study participants.

ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.

In persons with biopsy-confirmed NASH, the probability of disease resolution was more than 3X greater after RGB or SG vs lifestyle intervention at 52 weeks.